{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:14:30Z","timestamp":1792095270959,"version":"4.4.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Considering the high clinical and forensic relevance of pharmaco-adherence during lisdexamphetamine (LDX) treatment for attention-deficit\/hyperactivity disorder (ADHD), the aim here was to evaluate hair analysis as a tool for monitoring compliance in patients currently undergoing long term treatment with LDX, by detecting possible interruptions of medication intake or changes in dosage. For this purpose, a total of 24 patients from an outpatient clinic for ADHD were recruited. Hair and urine samples were taken after three consecutive therapy sessions over a 7-month period and analyzed for amphetamine (AMP) enantiomers and other drugs, using chiral and achiral liquid chromatography-tandem mass spectrometry (LC-MS\/MS). Participants also provided information on the condition of their hair, the consumption of illegal psychotropic substances and the regularity of taking LDX. Two participants withdrew from the study early. Urine analyses were positive for D-AMP in all urine samples and therapy sessions, except in two patients who did not take LDX on a daily basis. D-AMP was detected in all hair samples; however, no correlation was found between prescribed dose\/day and D-AMP concentrations in proximal hair segments. Qualitative interpretation of hair analysis showed that 18 of the 22 study completers were compliant concerning the intake of LDX without additional consumption of illegal D,L-AMP. Analysis of urine taken during the therapy sessions showed no correlation between D-AMP concentrations and prescribed dosage, with or without normalization for creatinine. In conclusion, chiral LC-MS\/MS hair analysis might represent a non-invasive way to confirm LDX use within the approximate period covered by the hair segment tested, but it does not allow for quantitative therapeutic drug monitoring because of interindividual variability of concentrations in hair. Drug concentrations in hair at different stages of long-term treatment should thus be interpreted with caution by clinicians and forensic experts alike when making assessments of treatment adherence.<\/jats:p>","DOI":"10.1371\/journal.pone.0248747","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T17:24:56Z","timestamp":1617125096000},"page":"e0248747","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the reliability of hair analysis in monitoring the compliance of ADHD patients under treatment with Lisdexamphetamine"],"prefix":"10.1371","volume":"16","author":[{"given":"Marianne","family":"Haedener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-1304","authenticated-orcid":true,"given":"Wolfgang","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Liebrenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wuethrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-6807","authenticated-orcid":true,"given":"Anna","family":"Buadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"6","key":"pone.0248747.ref001","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1087054715618791","article-title":"Comparing Methods to Determine Persistence of Childhood ADHD Into Adulthood: A Prospective, Population-Based Study","volume":"22","author":"WJ Barbaresi","year":"2018","journal-title":"J Atten Disord"},{"key":"pone.0248747.ref002","doi-asserted-by":"crossref","unstructured":"Cooper D, Moisan J Fau\u2014Gregoire J-P, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. 2007(1555\u20132101 (Electronic)).","DOI":"10.4088\/JCP.v68n0601"},{"key":"pone.0248747.ref003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-76593-8","volume-title":"Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection","author":"M Burnier","year":"2018"},{"issue":"1","key":"pone.0248747.ref004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3810\/pgm.2010.01.2112","article-title":"Review of medication adherence in children and adults with ADHD","volume":"122","author":"LD Adler","year":"2010","journal-title":"Postgrad Med"},{"key":"pone.0248747.ref005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-244X-10-67","article-title":"European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD","volume":"10","author":"SJ Kooij","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"6","key":"pone.0248747.ref006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present\u2014a pharmacological and clinical perspective","volume":"27","author":"DJ Heal","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"2","key":"pone.0248747.ref007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mp.2008.90","article-title":"Potential adverse effects of amphetamine treatment on brain and behavior: a review","volume":"14","author":"SM Berman","year":"2009","journal-title":"Mol Psychiatry"},{"key":"pone.0248747.ref008","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-48624-5","volume-title":"Neuro-\/Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie","author":"M Gerlach","year":"2016"},{"key":"pone.0248747.ref009","unstructured":"_Schweizerisches_Heilmittelinstitut S. Elvanse\u00ae, Kapseln (Lisdexamphetamini dimesylas) [https:\/\/www.swissmedic.ch\/zulassungen\/00153\/00189\/00200\/02036\/index.html?lang=de."},{"issue":"17","key":"pone.0248747.ref010","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/jama.2016.15380","article-title":"Association Between Prescription of Major Psychotropic Medications and Violent Reoffending After Prison Release","volume":"316","author":"Z Chang","year":"2016","journal-title":"JAMA"},{"key":"pone.0248747.ref011","doi-asserted-by":"crossref","unstructured":"Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. 1999(0149\u20132918 (Print)).","DOI":"10.1016\/S0149-2918(99)80026-5"},{"key":"pone.0248747.ref012","doi-asserted-by":"crossref","unstructured":"Garber MC, Nau Dp Fau\u2014Erickson SR, Erickson Sr Fau\u2014Aikens JE, Aikens Je Fau\u2014Lawrence JB, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. 2004(0025\u20137079 (Print)).","DOI":"10.1097\/01.mlr.0000129496.05898.02"},{"key":"pone.0248747.ref013","doi-asserted-by":"crossref","unstructured":"Lam WY, Fresco P. Medication Adherence Measures: An Overview. 2015(2314\u20136141 (Electronic)).","DOI":"10.1155\/2015\/217047"},{"issue":"2","key":"pone.0248747.ref014","doi-asserted-by":"crossref","first-page":"e23316","DOI":"10.1002\/ajhb.23316","article-title":"The biology of human hair: A multidisciplinary review","volume":"32","author":"SL Koch","year":"2020","journal-title":"American Journal of Human Biology"},{"issue":"2","key":"pone.0248747.ref015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clinthera.2010.02.011","article-title":"Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit\/hyperactivity disorder: a single-dose, randomized, open-label, crossover study","volume":"32","author":"SW Boellner","year":"2010","journal-title":"Clin Ther"},{"issue":"6","key":"pone.0248747.ref016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/11588190-000000000-00000","article-title":"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men","volume":"31","author":"JC Ermer","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"1","key":"pone.0248747.ref017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1185\/030079908X242737","article-title":"Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers","volume":"24","author":"SM Krishnan","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"pone.0248747.ref018","first-page":"745","article-title":"Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers","volume":"28","author":"SM Krishnan","year":"2008","journal-title":"Clin Drug Investig"},{"issue":"7","key":"pone.0248747.ref019","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/rcm.6844","article-title":"Isotope-dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis","volume":"28","author":"M Thevis","year":"2014","journal-title":"Rapid Commun Mass Spectrom"},{"key":"pone.0248747.ref020","article-title":"Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC-MS\/MS","author":"E Comiran","year":"2016","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"pone.0248747.ref021","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/dta.2208","article-title":"Chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse(R) therapy and identification after controlled low-dose application","volume":"10","author":"TM Binz","year":"2018","journal-title":"Drug Test Anal"},{"key":"pone.0248747.ref022","doi-asserted-by":"crossref","unstructured":"Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. 2006(1083\u20134087 (Print)).","DOI":"10.18553\/jmcp.2006.12.8.649"},{"key":"pone.0248747.ref023","unstructured":"Kertes J, Dushenat M Fau\u2014Vesterman JL, Vesterman Jl Fau\u2014Lemberger J, Lemberger J Fau\u2014Bregman J, Bregman J Fau\u2014Friedman N, Friedman N. Factors contributing to compliance with osteoporosis medication. 2008(1565\u20131088 (Print))."},{"issue":"5","key":"pone.0248747.ref024","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00216-016-0056-1","article-title":"Accelerated quantification of amphetamine enantiomers in human urine using chiral liquid chromatography and on-line column-switching coupled with tandem mass spectrometry","volume":"409","author":"M H\u00e4dener","year":"2017","journal-title":"Analytical and bioanalytical chemistry"},{"issue":"2","key":"pone.0248747.ref025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.2009.03576.x","article-title":"Stereoselectivity in the human metabolism of methamphetamine","volume":"69","author":"L Li","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0248747.ref026","unstructured":"Beckman_Coulter. Creatinine OSR6178\/OSR6678\u2014Technical Document 2010 [https:\/\/www.beckmancoulter.com\/wsrportal\/techdocs?docname=\/cis\/BAOSR6x78A\/%25%25\/EN_CREATININE.pdf."},{"key":"pone.0248747.ref027","article-title":"Accelerated quantification of amphetamine enantiomers in human urine using chiral liquid chromatography and on-line column-switching coupled with tandem mass spectrometry","author":"M Hadener","year":"2016","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"pone.0248747.ref028","first-page":"195","article-title":"Determination of the enantiomeric composition of amphetamine standards","volume":"86","author":"TJ Gelmi","year":"2019","journal-title":"Toxichem Krimtech"},{"key":"pone.0248747.ref029","unstructured":"Food_and_Drug_Administration. Guidance for Industry: Bioanalytical Method Validation 2001 [1\u201322]. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070107.pdf."},{"key":"pone.0248747.ref030","unstructured":"European_Medicines_Agency. Guideline on bioanalytical method validation 2011 [1\u201323]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf."},{"issue":"1","key":"pone.0248747.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/33.1.1","article-title":"Normalization of urinary drug concentrations with specific gravity and creatinine","volume":"33","author":"EJ Cone","year":"2009","journal-title":"J Anal Toxicol"},{"issue":"8","key":"pone.0248747.ref032","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jat\/bkw092","article-title":"Urine creatinine concentrations in drug monitoring participants and hospitalized patients","volume":"40","author":"SA Love","year":"2016","journal-title":"Journal of analytical toxicology"},{"issue":"6","key":"pone.0248747.ref033","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/1087054716676342","article-title":"Adults With Persistent ADHD: Gender and Psychiatric Comorbidities-A Population-Based Longitudinal Study","volume":"22","author":"K Yoshimasu","year":"2018","journal-title":"J Atten Disord"},{"issue":"4","key":"pone.0248747.ref034","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","article-title":"The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication","volume":"163","author":"RC Kessler","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"5 Suppl","key":"pone.0248747.ref035","doi-asserted-by":"crossref","first-page":"3s","DOI":"10.1177\/1087054711435361","article-title":"Distinguishing comorbidity and successful management of adult ADHD","volume":"16","author":"JJ Kooij","year":"2012","journal-title":"J Atten Disord"},{"issue":"2","key":"pone.0248747.ref036","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0193-953X(03)00113-8","article-title":"Attention-deficit\/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues","volume":"27","author":"TE Wilens","year":"2004","journal-title":"Psychiatr Clin North Am"},{"key":"pone.0248747.ref037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev.med.53.082901.103945","article-title":"Attention deficit\/hyperactivity disorder across the lifespan","volume":"53","author":"TE Wilens","year":"2002","journal-title":"Annu Rev Med"},{"issue":"1","key":"pone.0248747.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cap.1993.3.1","article-title":"Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder","volume":"3","author":"GD Gammon","year":"1993","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"pone.0248747.ref039","volume-title":"Attention deficit hyperactivity disorder in adults: The latest assessment and treatment strategies","author":"RA Barkley","year":"2010"},{"issue":"2","key":"pone.0248747.ref040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jat\/21.2.176","article-title":"Urinary dextroamphetamine in adult attention deficit\/hyperactivity disorder","volume":"21","author":"A Poklis","year":"1997","journal-title":"J Anal Toxicol"},{"issue":"6","key":"pone.0248747.ref041","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jat\/22.6.481","article-title":"Urinary excretion of d-amphetamine following oral doses in humans: implications for urine drug testing","volume":"22","author":"A Poklis","year":"1998","journal-title":"J Anal Toxicol"},{"issue":"6","key":"pone.0248747.ref042","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/15563650.2015.1049355","article-title":"CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants","volume":"53","author":"V Haufroid","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"pone.0248747.ref043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2014.06.053","article-title":"Sample preparation methods for determination of drugs of abuse in hair samples: A review","volume":"857","author":"S Vogliardi","year":"2015","journal-title":"Anal Chim Acta"},{"key":"pone.0248747.ref044","first-page":"1","article-title":"Recent trends in analytical methods and separation techniques for drugs of abuse in hair","volume":"856","author":"T Baciu","year":"2015","journal-title":"Anal Chim Acta"},{"issue":"1\u20133","key":"pone.0248747.ref045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0379-0738(93)90256-A","article-title":"Mechanisms of drug incorporation into hair","volume":"63","author":"GL Henderson","year":"1993","journal-title":"Forensic Sci Int"},{"issue":"9","key":"pone.0248747.ref046","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2007.04.015","article-title":"Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study","volume":"62","author":"J Biederman","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"9","key":"pone.0248747.ref047","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0091270009357346","article-title":"Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers","volume":"50","author":"J Ermer","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"pone.0248747.ref048","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/FTD.0000000000000343","article-title":"Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink","volume":"38","author":"J Ermer","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"4","key":"pone.0248747.ref049","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/FTD.0000000000000296","article-title":"A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function","volume":"38","author":"J Ermer","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"9","key":"pone.0248747.ref050","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/clinchem\/45.9.1485","article-title":"Codeine concentration in hair after oral administration is dependent on melanin content","volume":"45","author":"R Kronstrand","year":"1999","journal-title":"Clin Chem"},{"issue":"7","key":"pone.0248747.ref051","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jat\/25.7.594","article-title":"Incorporation of selegiline metabolites into hair after oral selegiline intake","volume":"25","author":"R Kronstrand","year":"2001","journal-title":"J Anal Toxicol"},{"issue":"3","key":"pone.0248747.ref052","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/27.3.135","article-title":"Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication","volume":"27","author":"R Kronstrand","year":"2003","journal-title":"J Anal Toxicol"},{"key":"pone.0248747.ref053","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.aca.2012.01.042","article-title":"Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration","volume":"726","author":"A Polettini","year":"2012","journal-title":"Anal Chim Acta"},{"issue":"1","key":"pone.0248747.ref054","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.forsciint.2007.06.023","article-title":"Influence of bleaching on the enantiomeric disposition of amphetamine-type stimulants in hair","volume":"176","author":"LF Martins","year":"2008","journal-title":"Forensic Sci Int"},{"issue":"1\u20133","key":"pone.0248747.ref055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.forsciint.2010.06.023","article-title":"Effects of repeated hair washing and a single hair dyeing on concentrations of methamphetamine and amphetamine in human hairs","volume":"206","author":"S Baeck","year":"2011","journal-title":"Forensic Sci Int"},{"issue":"4","key":"pone.0248747.ref056","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1099-0801(199906)13:4<257::AID-BMC830>3.0.CO;2-V","article-title":"High-performance liquid chromatography study on effects of permanent wave, dye and decolorant treatments on methamphetamine and amphetamine in hair","volume":"13","author":"N Takayama","year":"1999","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"pone.0248747.ref057","first-page":"545","article-title":"The current status of sweat testing for drugs of abuse: a review","volume":"20","author":"N De Giovanni","year":"2013","journal-title":"Curr Med Chem"},{"key":"pone.0248747.ref058","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/PPA.S42145","article-title":"Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence?","volume":"8","author":"S McCarthy","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"pone.0248747.ref059","doi-asserted-by":"crossref","unstructured":"Lakhan SE, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. 2012(2162\u20133279 (Electronic)).","DOI":"10.1002\/brb3.78"},{"key":"pone.0248747.ref060","doi-asserted-by":"crossref","unstructured":"Sawada N, Uchida H Fau\u2014Suzuki T, Suzuki T Fau\u2014Watanabe K, Watanabe K Fau\u2014Kikuchi T, Kikuchi T Fau\u2014Handa T, Handa T Fau\u2014Kashima H, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. 2009(1471-244X (Electronic)).","DOI":"10.1186\/1471-244X-9-38"},{"issue":"5","key":"pone.0248747.ref061","first-page":"236","article-title":"Adherence to antidepressants: A review of the literature","volume":"6","author":"MJ Martin-Vazquez","year":"2016","journal-title":"Neuropsychiatry"},{"key":"pone.0248747.ref062","unstructured":"Weber J, Schaub J, Bumann-Pacozzi CM, Sacher K. Anordnung und Vollzug station\u00e4rer therapeutischer Massnahmen gem\u00e4ss Art. 59 StGB mit Fokus auf geschlossene Strafanstalten bzw. geschlossene Massnahmeneinrichtungen. Studie zuhanden der Nationalen Kommission zur Verh\u00fctung von Folter (NKVF) 2016 [https:\/\/www.humanrights.ch\/cms\/upload\/pdf\/170809_Weber-Schaub-Bumann-Sacher_Studie.pdf."},{"issue":"680","key":"pone.0248747.ref063","article-title":"Conflicting Priorities Between Risk Management and Treatment of Schizophrenia in Swiss Forensic Services\u2014A Case Report","volume":"9","author":"S Steinau","year":"2018","journal-title":"Frontiers in Psychiatry"},{"issue":"1","key":"pone.0248747.ref064","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0306624X09356683","article-title":"Risk Factors for Overall Recidivism and Severity of Recidivism in Serious Juvenile Offenders","volume":"55","author":"E Mulder","year":"2011","journal-title":"International Journal of Offender Therapy and Comparative Criminology"},{"key":"pone.0248747.ref065","first-page":"157","volume-title":"Handbook of Violence Risk Assessment. International Perspectives on Forensic Mental Health","author":"KS Douglas","year":"2014"},{"issue":"1","key":"pone.0248747.ref066","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0306624X09359502","article-title":"Factors Associated With Recidivism Among Offenders With Mental Illness","volume":"55","author":"ED Castillo","year":"2011","journal-title":"International Journal of Offender Therapy and Comparative Criminology"},{"issue":"4","key":"pone.0248747.ref067","first-page":"513","article-title":"Challenges and Limitations to Treating ADHD in Incarcerated Populations","volume":"44","author":"XL Ruan","year":"2016","journal-title":"Journal of the American Academy of Psychiatry and the Law"},{"issue":"2","key":"pone.0248747.ref068","first-page":"164","article-title":"COMMENTARY: Challenges and Limitations to Treating ADHD in Incarcerated Populations","volume":"44","author":"RCW Hall","year":"2016","journal-title":"Journal of the American Academy of Psychiatry and the Law"},{"issue":"2","key":"pone.0248747.ref069","first-page":"151","article-title":"Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine)","volume":"44","author":"JA Mattes","year":"2016","journal-title":"Journal of the American Academy of Psychiatry and the Law"},{"issue":"21","key":"pone.0248747.ref070","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for Attention Deficit-Hyperactivity Disorder and Criminality","volume":"367","author":"P Lichtenstein","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"pone.0248747.ref071","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00331","article-title":"Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis","volume":"9","author":"S Baggio","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"pone.0248747.ref072","volume-title":"Contemporary Trends in ADHD Research","author":"R Eme","year":"2012"},{"key":"pone.0248747.ref073","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1858-9","article-title":"Identification and treatment of offenders with attention-deficit\/hyperactivity disorder in the prison population: a practical approach based upon expert consensus","volume":"18","author":"S Young","year":"2018","journal-title":"Bmc Psychiatry"},{"issue":"2","key":"pone.0248747.ref074","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020262","article-title":"Chiral Drug Analysis in Forensic Chemistry: An Overview","volume":"23","author":"C Ribeiro","year":"2018","journal-title":"Molecules"},{"issue":"2","key":"pone.0248747.ref075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11757-014-0302-3","article-title":"Die invalidenversicherungsrechtliche Begutachtung in der Schweiz vor dem Hintergrund der letzten Gesetzesrevision und neueren Rechtsprechung","volume":"9","author":"C Canela","year":"2015","journal-title":"Forensische Psychiatrie, Psychologie, Kriminologie"},{"issue":"1","key":"pone.0248747.ref076","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10926-018-9766-x","article-title":"Evaluation of a Placement Coaching Program for Recipients of Disability Insurance Benefits in Switzerland","volume":"29","author":"T Hagen","year":"2019","journal-title":"Journal of Occupational Rehabilitation"},{"issue":"1","key":"pone.0248747.ref077","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0094-1190(02)00017-7","article-title":"Car ownership, employment, and earnings","volume":"52","author":"S Raphael","year":"2002","journal-title":"Journal of Urban Economics"},{"key":"pone.0248747.ref078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jue.2016.10.003","article-title":"Does Enhanced Mobility of Young People Improve Employment and Housing Outcomes? Evidence from a Large and Controlled Experiment in France","volume":"97","author":"J Le Gallo","year":"2017","journal-title":"Journal of Urban Economics"},{"issue":"5","key":"pone.0248747.ref079","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0001-4575(88)90020-6","article-title":"Effects of License Revocation on Drunk-Driving Offenders","volume":"20","author":"HL Ross","year":"1988","journal-title":"Accident Analysis and Prevention"},{"key":"pone.0248747.ref080","article-title":"Suspended licenses, suspended lives: the impact of drug-related driver\u2019s license suspensions on traffic fatalities","author":"T Sohoni","year":"2019","journal-title":"Journal of Crime & Justice"},{"issue":"Suppl 1","key":"pone.0248747.ref081","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/dta.1627","article-title":"Is one hair lock really representative?","volume":"6","author":"F Dussy","year":"2014","journal-title":"Drug Test Anal"},{"issue":"10","key":"pone.0248747.ref082","first-page":"1594","volume":"9","author":"U Meier","year":"2017","journal-title":"Distribution pattern of ethyl glucuronide and caffeine concentrations over the scalp of a single person in a forensic context"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:55:30Z","timestamp":1698148530000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248747"}},"subtitle":[],"editor":[{"given":"Pasquale","family":"Avino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248747","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}